董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| H Kevin McCann | 男 | Independent Non-Executive Director | 85 | 11.73万美元 | 未持股 | 2026-05-11 |
| Mark Nelson | 男 | Independent Non-Executive Director, Interim Chair | 66 | 12.95万美元 | 362.88 | 2026-05-11 |
| Jann Skinner | 女 | Independent Non-Executive Director | 69 | 15.08万美元 | 59.50 | 2026-05-11 |
| David Gill | 男 | Non-Executive Director | -- | 未披露 | 未持股 | 2026-05-11 |
| David Gill | 男 | Non-Executive Director | 71 | 未披露 | 未持股 | 2026-05-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christian Behrenbruch | 男 | Managing Director and Group CEO | 51 | 126.17万美元 | 2132.90 | 2026-05-11 |
| Darren Patti | 男 | Group Chief Operating Officer | 54 | 84.92万美元 | 2.56 | 2026-05-11 |
| Darren Smith | 男 | Group Chief Financial Officer | 60 | 101.81万美元 | 0.76 | 2026-05-11 |
| David Cade | 男 | Group Chief Medical Officer | 57 | 54.52万美元 | 37.31 | 2026-05-11 |
董事简历
中英对照 | 中文 | 英文- H Kevin McCann
-
H Kevin McCann，自2017年9月起担任本公司非执行董事兼董事会主席。此前，McCann先生曾于1996年12月至2016年3月担任Macquarie Group和Macquarie Bank Limited的董事长，于2000年1月至2013年10月担任Origin Energy Limited的董事长，于2001年6月至2010年6月以及于2015年6月至2018年6月担任Sydney Harbour Federation Trust的董事长，于2002年5月至2013年4月担任Bluescope Steel Ltd的董事，并于2020年2月至2021年11月担任E & P Financial Group Ltd的董事。他还曾于2010年6月至2020年6月担任悉尼大学美国研究中心主任，并于2018年1月至2023年12月担任悉尼歌剧院受托人。自2010年4月起担任Champions of Change Founding Group成员，自2015年8月起担任Sydney Harbour Foundation Management主席，自2018年11月起担任China Matters主席，自2020年12月起担任澳大利亚Haydn Ensemble董事，自2022年6月起担任Blueprint Institute主席和董事会顾问。McCann先生于1970年至2004年作为Allens Arthur Robinson（现为Allens）的合伙人从事商业律师业务，并于1995年至2004年担任Partners的董事长。McCann先生获得了悉尼大学的文学学士学位和法律学士学位（荣誉）以及哈佛大学的法律硕士学位，并被授予悉尼大学的荣誉法学博士学位。他是澳大利亚公司董事协会的终身研究员。我们认为，McCann先生在澳大利亚一些最受认可的公司的丰富董事会经验使他有资格担任Telix Pharmaceuticals Limited董事会成员。
H Kevin McCann,has served as a Non-Executive Director and Chairman of Telix Pharmaceuticals Limited board of directors since September 2017. Previously, Mr. McCann served as Chairman of Macquarie Group and Macquarie Bank Limited from December 1996 to March 2016, Chairman of Origin Energy Limited from January 2000 to October 2013, Chairman of the Sydney Harbour Federation Trust from June 2001 to June 2010 and from June 2015 to June 2018, Director of Bluescope Steel Ltd from May 2002 to April 2013, Director of E&P Financial Group Ltd from February 2020 to November 2021 and Chairman of China Matters from November 2018 to December 2023. He was also a Director of the United States Studies Centre at the University of Sydney from June 2010 to June 2020 and was a Trustee of the Sydney Opera House from January 2018 to December 2023. He has served as a Member of Champions of Change Founding Group since April 2010, Chairman of Sydney Harbour Foundation Management since August 2015, Director of Australian Haydn Ensemble since December 2020 and Chair and Board Advisor of Blueprint Institute since June 2022. Mr. McCann practiced as a commercial lawyer as a partner of Allens Arthur Robinson (now Allens) from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. Mr. McCann received a Bachelor of Arts and a Bachelor of Law (Honors) from Sydney University and a Master of Law from Harvard University and was awarded an honorary Doctor of Laws from the University of Sydney. He is a Life Fellow of the Australian Institute of Company Directors. - H Kevin McCann，自2017年9月起担任本公司非执行董事兼董事会主席。此前，McCann先生曾于1996年12月至2016年3月担任Macquarie Group和Macquarie Bank Limited的董事长，于2000年1月至2013年10月担任Origin Energy Limited的董事长，于2001年6月至2010年6月以及于2015年6月至2018年6月担任Sydney Harbour Federation Trust的董事长，于2002年5月至2013年4月担任Bluescope Steel Ltd的董事，并于2020年2月至2021年11月担任E & P Financial Group Ltd的董事。他还曾于2010年6月至2020年6月担任悉尼大学美国研究中心主任，并于2018年1月至2023年12月担任悉尼歌剧院受托人。自2010年4月起担任Champions of Change Founding Group成员，自2015年8月起担任Sydney Harbour Foundation Management主席，自2018年11月起担任China Matters主席，自2020年12月起担任澳大利亚Haydn Ensemble董事，自2022年6月起担任Blueprint Institute主席和董事会顾问。McCann先生于1970年至2004年作为Allens Arthur Robinson（现为Allens）的合伙人从事商业律师业务，并于1995年至2004年担任Partners的董事长。McCann先生获得了悉尼大学的文学学士学位和法律学士学位（荣誉）以及哈佛大学的法律硕士学位，并被授予悉尼大学的荣誉法学博士学位。他是澳大利亚公司董事协会的终身研究员。我们认为，McCann先生在澳大利亚一些最受认可的公司的丰富董事会经验使他有资格担任Telix Pharmaceuticals Limited董事会成员。
- H Kevin McCann,has served as a Non-Executive Director and Chairman of Telix Pharmaceuticals Limited board of directors since September 2017. Previously, Mr. McCann served as Chairman of Macquarie Group and Macquarie Bank Limited from December 1996 to March 2016, Chairman of Origin Energy Limited from January 2000 to October 2013, Chairman of the Sydney Harbour Federation Trust from June 2001 to June 2010 and from June 2015 to June 2018, Director of Bluescope Steel Ltd from May 2002 to April 2013, Director of E&P Financial Group Ltd from February 2020 to November 2021 and Chairman of China Matters from November 2018 to December 2023. He was also a Director of the United States Studies Centre at the University of Sydney from June 2010 to June 2020 and was a Trustee of the Sydney Opera House from January 2018 to December 2023. He has served as a Member of Champions of Change Founding Group since April 2010, Chairman of Sydney Harbour Foundation Management since August 2015, Director of Australian Haydn Ensemble since December 2020 and Chair and Board Advisor of Blueprint Institute since June 2022. Mr. McCann practiced as a commercial lawyer as a partner of Allens Arthur Robinson (now Allens) from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. Mr. McCann received a Bachelor of Arts and a Bachelor of Law (Honors) from Sydney University and a Master of Law from Harvard University and was awarded an honorary Doctor of Laws from the University of Sydney. He is a Life Fellow of the Australian Institute of Company Directors.
- Mark Nelson
-
Mark Nelson，自2017年9月起担任非执行董事。Nelson博士自2012年1月起担任喀里多尼亚投资集团主席，自2002年8月起担任喀里多尼亚基金会董事。他曾于1992年2月至2012年1月担任喀里多尼亚投资集团首席执行官兼联席首席投资官。他还自2005年10月起担任Kaldor公共艺术项目主任，自2007年10月起担任Florey神经科学研究所所长，自2018年2月起担任Mindgardens神经科学网络主任，自2019年起担任澳大利亚艺术展览主席。Nelson博士在墨尔本大学获得理学学士学位，在剑桥大学获得哲学硕士学位，在墨尔本大学获得博士学位。我们认为Nelson博士在资本、股权和投资市场，包括生命科学行业的资格和经验，使他有资格担任Telix Pharmaceuticals Limited董事会成员。
Mark Nelson,has served as a Non-Executive Director since September 2017. Dr. Nelson has served as Chairman of the Caledonia Investments Group since January 2012, and as a Director of The Caledonia Foundation since August 2002. He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group from February 1992 to January 2012. He has also served as Director of Kaldor Public Art Projects since October 2005, Governor of the Florey Neurosciences Institute since October 2007, Director of the Mindgardens Neuroscience Network since February 2018 and Chairman of Art Exhibitions Australia since 2019. Dr. Nelson received his B.Sc. from the University of Melbourne, his M.Phil from the University of Cambridge and his Ph.D. from the University of Melbourne. - Mark Nelson，自2017年9月起担任非执行董事。Nelson博士自2012年1月起担任喀里多尼亚投资集团主席，自2002年8月起担任喀里多尼亚基金会董事。他曾于1992年2月至2012年1月担任喀里多尼亚投资集团首席执行官兼联席首席投资官。他还自2005年10月起担任Kaldor公共艺术项目主任，自2007年10月起担任Florey神经科学研究所所长，自2018年2月起担任Mindgardens神经科学网络主任，自2019年起担任澳大利亚艺术展览主席。Nelson博士在墨尔本大学获得理学学士学位，在剑桥大学获得哲学硕士学位，在墨尔本大学获得博士学位。我们认为Nelson博士在资本、股权和投资市场，包括生命科学行业的资格和经验，使他有资格担任Telix Pharmaceuticals Limited董事会成员。
- Mark Nelson,has served as a Non-Executive Director since September 2017. Dr. Nelson has served as Chairman of the Caledonia Investments Group since January 2012, and as a Director of The Caledonia Foundation since August 2002. He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group from February 1992 to January 2012. He has also served as Director of Kaldor Public Art Projects since October 2005, Governor of the Florey Neurosciences Institute since October 2007, Director of the Mindgardens Neuroscience Network since February 2018 and Chairman of Art Exhibitions Australia since 2019. Dr. Nelson received his B.Sc. from the University of Melbourne, his M.Phil from the University of Cambridge and his Ph.D. from the University of Melbourne.
- Jann Skinner
-
Jann Skinner，自2018年6月起担任非执行董事。斯金纳女士在1987年至2004年期间是普华永道会计师事务所的合伙人。她自2004年6月起担任Create Foundation Limited董事。她还曾于2014年10月至2024年5月担任QBE Insurance Group Limited非执行董事，并于2017年4月至2023年4月担任HSBC Bank Australia Limited董事。Skinner女士是澳大利亚和新西兰特许会计师协会和澳大利亚公司董事协会的资深会员。她在新南威尔士大学获得商学学士学位（BCoM）。我们相信，Skinner女士在审计和会计方面的专业知识以及之前的董事会经验使她有资格担任我们的董事会成员。
Jann Skinner,has served as a Non-Executive Director since June 2018. Ms. Skinner was a partner at PricewaterhouseCoopers from 1987 to 2004. She has served as Director of Create Foundation Limited since June 2004. She also served as Non-Executive Director of QBE Insurance Group Limited from October 2014 to May 2024 and Director of HSBC Bank Australia Limited from April 2017 to April 2023. Ms. Skinner is a Fellow of both Chartered Accountants Australia & New Zealand and the Australian Institute of Company Directors. She received her Bachelor of Commerce (BCom) from the University of New South Wales. - Jann Skinner，自2018年6月起担任非执行董事。斯金纳女士在1987年至2004年期间是普华永道会计师事务所的合伙人。她自2004年6月起担任Create Foundation Limited董事。她还曾于2014年10月至2024年5月担任QBE Insurance Group Limited非执行董事，并于2017年4月至2023年4月担任HSBC Bank Australia Limited董事。Skinner女士是澳大利亚和新西兰特许会计师协会和澳大利亚公司董事协会的资深会员。她在新南威尔士大学获得商学学士学位（BCoM）。我们相信，Skinner女士在审计和会计方面的专业知识以及之前的董事会经验使她有资格担任我们的董事会成员。
- Jann Skinner,has served as a Non-Executive Director since June 2018. Ms. Skinner was a partner at PricewaterhouseCoopers from 1987 to 2004. She has served as Director of Create Foundation Limited since June 2004. She also served as Non-Executive Director of QBE Insurance Group Limited from October 2014 to May 2024 and Director of HSBC Bank Australia Limited from April 2017 to April 2023. Ms. Skinner is a Fellow of both Chartered Accountants Australia & New Zealand and the Australian Institute of Company Directors. She received her Bachelor of Commerce (BCom) from the University of New South Wales.
- David Gill
-
David Gill，在资本市场、业务扩展、治理和公司扭亏为盈战略方面拥有深厚的专业知识，曾担任多家上市公司的首席财务官或总裁，包括EndoChoice Holdings，Inc.（NYSE：GI，被波士顿科学收购）、INC Research（NASDAQ：INCR，现为Syneos Health）以及CTI Molecular Imaging（NASDAQ：CTMI，被Siemens收购）。他拥有维克森林大学会计学学士学位和埃默里大学MBA学位。
David Gill,has deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoice Holdings, Inc. (NYSE: GI, acquired by Boston Scientific), INC Research (NASDAQ: INCR, now Syneos Health), and CTI Molecular Imaging (NASDAQ: CTMI, acquired by Siemens). He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University. - David Gill，在资本市场、业务扩展、治理和公司扭亏为盈战略方面拥有深厚的专业知识，曾担任多家上市公司的首席财务官或总裁，包括EndoChoice Holdings，Inc.（NYSE：GI，被波士顿科学收购）、INC Research（NASDAQ：INCR，现为Syneos Health）以及CTI Molecular Imaging（NASDAQ：CTMI，被Siemens收购）。他拥有维克森林大学会计学学士学位和埃默里大学MBA学位。
- David Gill,has deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoice Holdings, Inc. (NYSE: GI, acquired by Boston Scientific), INC Research (NASDAQ: INCR, now Syneos Health), and CTI Molecular Imaging (NASDAQ: CTMI, acquired by Siemens). He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.
- David Gill
-
David Gill，自2018年2月起担任Evolus， Inc.董事会成员。从2021年2月到2021年10月，Gill先生在医疗设备和生命科学行业拥有超过30年的经验，最近担任Perspectum， Ltd的首席财务官，这是一家医疗技术公司，改变了代谢疾病和癌症的临床管理。他目前还担任Y-mAbs Therapeutics， Inc.以及几家私人公司的董事。此前，他于2019年9月至2021年10月担任Strongbridge Biopharma， PLC董事会成员，2015年1月至2019年7月担任Histogenics， Inc.董事会成员，2012年4月至2020年4月担任Melinta Therapeutics， Inc.（f/k/a Cempra Inc.）董事会成员，2018年5月至2020年5月担任Strata Skin Sciences董事会成员。在职业生涯早期，他曾担任多家上市公司的各种高级行政领导职务，包括EndoChoice， Inc., NxStage Medical, Inc., CTI Molecular Imaging, Inc., Interland Inc.和Novoste Corporation。他持有Wake Forest University的会计学学士学位和Emory University的工商管理硕士学位，是一名注册会计师（非在职）。
David Gill,served as the Chief Financial Officer of Perspectum, Ltd, a healthcare technology company which transforms the clinical management of metabolic disease and cancer. Mr. Gill also currently serves as a director of Y-mAbs Therapeutics, Inc. as well as several private companies. Previously he served on the board of directors of Strongbridge Biopharma, PLC from September 2019 to October 2021, Histogenics, Inc. from January 2015 to July 2019, Melinta Therapeutics, Inc (f/k/a Cempra Inc. from April 2012 to April 2020, and Strata Skin Sciences from May 2018 to May 2020). Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several publicly-traded companies, including EndoChoice, Inc., NxStage Medical, Inc., CTI Molecular Imaging, Inc., Interland Inc. and Novoste Corporation. Mr. Gill holds a B.S. in Accounting from Wake Forest University and an M.B.A. from Emory University, and is a certified public accountant (inactive). - David Gill，自2018年2月起担任Evolus， Inc.董事会成员。从2021年2月到2021年10月，Gill先生在医疗设备和生命科学行业拥有超过30年的经验，最近担任Perspectum， Ltd的首席财务官，这是一家医疗技术公司，改变了代谢疾病和癌症的临床管理。他目前还担任Y-mAbs Therapeutics， Inc.以及几家私人公司的董事。此前，他于2019年9月至2021年10月担任Strongbridge Biopharma， PLC董事会成员，2015年1月至2019年7月担任Histogenics， Inc.董事会成员，2012年4月至2020年4月担任Melinta Therapeutics， Inc.（f/k/a Cempra Inc.）董事会成员，2018年5月至2020年5月担任Strata Skin Sciences董事会成员。在职业生涯早期，他曾担任多家上市公司的各种高级行政领导职务，包括EndoChoice， Inc., NxStage Medical, Inc., CTI Molecular Imaging, Inc., Interland Inc.和Novoste Corporation。他持有Wake Forest University的会计学学士学位和Emory University的工商管理硕士学位，是一名注册会计师（非在职）。
- David Gill,served as the Chief Financial Officer of Perspectum, Ltd, a healthcare technology company which transforms the clinical management of metabolic disease and cancer. Mr. Gill also currently serves as a director of Y-mAbs Therapeutics, Inc. as well as several private companies. Previously he served on the board of directors of Strongbridge Biopharma, PLC from September 2019 to October 2021, Histogenics, Inc. from January 2015 to July 2019, Melinta Therapeutics, Inc (f/k/a Cempra Inc. from April 2012 to April 2020, and Strata Skin Sciences from May 2018 to May 2020). Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several publicly-traded companies, including EndoChoice, Inc., NxStage Medical, Inc., CTI Molecular Imaging, Inc., Interland Inc. and Novoste Corporation. Mr. Gill holds a B.S. in Accounting from Wake Forest University and an M.B.A. from Emory University, and is a certified public accountant (inactive).
高管简历
中英对照 | 中文 | 英文- Christian Behrenbruch
Christian Behrenbruch是Telix Pharmaceuticals Limited的联合创始人之一，自2017年1月起担任集团首席执行官，并于2017年1月加入Telix Pharmaceuticals Limited董事会，担任董事总经理。他曾于2001年7月至2002年12月担任Mirada Solutions首席执行官，2003年8月至2006年9月担任CTI Molecular Imaging（现为Siemens Healthcare）总裁，2008年6月至2011年12月担任Fibron Technologies，Inc.首席执行官，2007年10月至2015年2月担任ImaginAB，Inc.首席执行官。2005年5月至2006年9月担任Siemens Molecular Imaging Ltd.董事，2007年7月至2009年6月担任Momentum Biosciences LLC董事，2009年5月至2011年2月担任Radius Health Ltd（现为Adaptix Ltd）董事，2015年10月至2021年5月担任Factor Therapeutics Limited董事，2016年5月至2020年2月担任Amplia Therapeutics Limited董事，2012年10月至2014年7月担任Cell Therapies Pty Ltd（与Peter MacCallum癌症中心合作）董事长。Behrenbruch博士拥有牛津大学生物医学工程哲学博士（PhD）、纽约大学、巴黎高等商学院和伦敦经济学院（TRIUM项目）联合授予的高级工商管理硕士（MBA）以及墨尔本大学的法学博士。Behrenbruch博士是澳大利亚工程师协会管理和生物医学学院的研究员，也是澳大利亚公司董事协会的毕业生。我们相信Behrenbruch博士的专业知识以及在医疗保健创业和执行领导力方面超过20年的经验使他有资格担任Telix Pharmaceuticals Limited董事会成员。
Christian Behrenbruch,is one of Telix Pharmaceuticals Limited Co-Founders, has served as Group Chief Executive Officer since January 2017 and joined Telix Pharmaceuticals Limited board of directors as Managing Director in January 2017. He has previously served as Chief Executive Officer at Mirada Solutions from July 2001 to December 2002, President at CTI Molecular Imaging (now Siemens Healthcare) from August 2003 to September 2006, Chief Executive Officer at Fibron Technologies, Inc. from June 2008 to December 2011 and Chief Executive Officer at ImaginAb, Inc from October 2007 to February 2015. He served as a Director at Siemens Molecular Imaging Ltd from May 2005 to September 2006, Momentum Biosciences LLC from July 2007 to June 2009, Radius Health Ltd (now Adaptix Ltd) from May 2009 to February 2011, Factor Therapeutics Limited from October 2015 to May 2021 and Amplia Therapeutics Limited from May 2016 to February 2020, and he was the Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre) from October 2012 to July 2014. Dr. Behrenbruch holds a Doctor of Philosophy (PhD) in biomedical engineering from the University of Oxford, an executive Master of Business Administration (MBA) jointly awarded from New York University, HEC Paris and the London School of Economics (TRIUM Program) and a Juris Doctor from the University of Melbourne. Dr. Behrenbruch is a Fellow of Engineers Australia in the management and biomedical colleges and a Graduate of the Australian Institute of Company Directors.- Christian Behrenbruch是Telix Pharmaceuticals Limited的联合创始人之一，自2017年1月起担任集团首席执行官，并于2017年1月加入Telix Pharmaceuticals Limited董事会，担任董事总经理。他曾于2001年7月至2002年12月担任Mirada Solutions首席执行官，2003年8月至2006年9月担任CTI Molecular Imaging（现为Siemens Healthcare）总裁，2008年6月至2011年12月担任Fibron Technologies，Inc.首席执行官，2007年10月至2015年2月担任ImaginAB，Inc.首席执行官。2005年5月至2006年9月担任Siemens Molecular Imaging Ltd.董事，2007年7月至2009年6月担任Momentum Biosciences LLC董事，2009年5月至2011年2月担任Radius Health Ltd（现为Adaptix Ltd）董事，2015年10月至2021年5月担任Factor Therapeutics Limited董事，2016年5月至2020年2月担任Amplia Therapeutics Limited董事，2012年10月至2014年7月担任Cell Therapies Pty Ltd（与Peter MacCallum癌症中心合作）董事长。Behrenbruch博士拥有牛津大学生物医学工程哲学博士（PhD）、纽约大学、巴黎高等商学院和伦敦经济学院（TRIUM项目）联合授予的高级工商管理硕士（MBA）以及墨尔本大学的法学博士。Behrenbruch博士是澳大利亚工程师协会管理和生物医学学院的研究员，也是澳大利亚公司董事协会的毕业生。我们相信Behrenbruch博士的专业知识以及在医疗保健创业和执行领导力方面超过20年的经验使他有资格担任Telix Pharmaceuticals Limited董事会成员。
- Christian Behrenbruch,is one of Telix Pharmaceuticals Limited Co-Founders, has served as Group Chief Executive Officer since January 2017 and joined Telix Pharmaceuticals Limited board of directors as Managing Director in January 2017. He has previously served as Chief Executive Officer at Mirada Solutions from July 2001 to December 2002, President at CTI Molecular Imaging (now Siemens Healthcare) from August 2003 to September 2006, Chief Executive Officer at Fibron Technologies, Inc. from June 2008 to December 2011 and Chief Executive Officer at ImaginAb, Inc from October 2007 to February 2015. He served as a Director at Siemens Molecular Imaging Ltd from May 2005 to September 2006, Momentum Biosciences LLC from July 2007 to June 2009, Radius Health Ltd (now Adaptix Ltd) from May 2009 to February 2011, Factor Therapeutics Limited from October 2015 to May 2021 and Amplia Therapeutics Limited from May 2016 to February 2020, and he was the Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre) from October 2012 to July 2014. Dr. Behrenbruch holds a Doctor of Philosophy (PhD) in biomedical engineering from the University of Oxford, an executive Master of Business Administration (MBA) jointly awarded from New York University, HEC Paris and the London School of Economics (TRIUM Program) and a Juris Doctor from the University of Melbourne. Dr. Behrenbruch is a Fellow of Engineers Australia in the management and biomedical colleges and a Graduate of the Australian Institute of Company Directors.
- Darren Patti
达伦·帕蒂，于2024年3月被任命为Telix Pharmaceuticals Limited集团首席运营官。在过渡担任这一职务之前，他于2021年3月至2024年3月期间担任Telix Pharmaceuticals Limited美洲业务的首席运营官兼总经理。此前，他曾于2019年11月至2021年3月担任Sofie Biosciences Inc.的运营副总裁，在担任这一职务之前，他在Sofie的15年任期内担任过许多其他领导职务，包括管理高产能PET制造设施和指导多个PET制造地点的区域运营。在加入Sofie之前，他曾在一家小型初创公司从事近距离放射治疗制造工作，该公司最终被华润巴德收购。他在放射性药物和设备制造方面拥有超过20年的经验，在网络管理和运营方面具有专长，包括新型放射性药物的制造、实施和合规。Patti博士拥有芝加哥伊利诺伊大学药学博士（Pharm.D.）和卡本代尔南伊利诺伊大学文学学士学位。他也是一名授权核药剂师，是美国多个州的持牌药剂师。
Darren Patti,was appointed as Telix Pharmaceuticals Limited Group Chief Operating Officer in March 2024. Prior to transitioning to this role, he was the Chief Operating Officer and General Manager of Telix Pharmaceuticals Limited Americas operations from March 2021 to March 2024. Previously, he served as Vice President of Operations at Sofie Biosciences Inc. from November 2019 to March 2021, and, preceding this role, he served in numerous other leadership capacities over his 15 year tenure at Sofie, including managing high capacity PET manufacturing facilities and directing regional operations over multiple PET manufacturing locations. Prior to joining Sofie, he worked in brachytherapy manufacturing with a small startup which was eventually acquired by CR Bard. He has over 20 years of experience in radiopharmaceutical and device manufacturing with expertise in network management and operations, including new radiopharmaceutical manufacturing, implementation and compliance. Dr. Patti holds a Doctor of Pharmacy (Pharm.D.) from the University of Illinois at Chicago and a Bachelor of Arts from Southern Illinois University at Carbondale. He is also an Authorized Nuclear Pharmacist and is a licensed pharmacist in multiple states within the United States.- 达伦·帕蒂，于2024年3月被任命为Telix Pharmaceuticals Limited集团首席运营官。在过渡担任这一职务之前，他于2021年3月至2024年3月期间担任Telix Pharmaceuticals Limited美洲业务的首席运营官兼总经理。此前，他曾于2019年11月至2021年3月担任Sofie Biosciences Inc.的运营副总裁，在担任这一职务之前，他在Sofie的15年任期内担任过许多其他领导职务，包括管理高产能PET制造设施和指导多个PET制造地点的区域运营。在加入Sofie之前，他曾在一家小型初创公司从事近距离放射治疗制造工作，该公司最终被华润巴德收购。他在放射性药物和设备制造方面拥有超过20年的经验，在网络管理和运营方面具有专长，包括新型放射性药物的制造、实施和合规。Patti博士拥有芝加哥伊利诺伊大学药学博士（Pharm.D.）和卡本代尔南伊利诺伊大学文学学士学位。他也是一名授权核药剂师，是美国多个州的持牌药剂师。
- Darren Patti,was appointed as Telix Pharmaceuticals Limited Group Chief Operating Officer in March 2024. Prior to transitioning to this role, he was the Chief Operating Officer and General Manager of Telix Pharmaceuticals Limited Americas operations from March 2021 to March 2024. Previously, he served as Vice President of Operations at Sofie Biosciences Inc. from November 2019 to March 2021, and, preceding this role, he served in numerous other leadership capacities over his 15 year tenure at Sofie, including managing high capacity PET manufacturing facilities and directing regional operations over multiple PET manufacturing locations. Prior to joining Sofie, he worked in brachytherapy manufacturing with a small startup which was eventually acquired by CR Bard. He has over 20 years of experience in radiopharmaceutical and device manufacturing with expertise in network management and operations, including new radiopharmaceutical manufacturing, implementation and compliance. Dr. Patti holds a Doctor of Pharmacy (Pharm.D.) from the University of Illinois at Chicago and a Bachelor of Arts from Southern Illinois University at Carbondale. He is also an Authorized Nuclear Pharmacist and is a licensed pharmacist in multiple states within the United States.
- Darren Smith
Darren Smith，自2022年8月起担任Telix Pharmaceuticals Limited Group 首席财务官。此前，他于2008年6月至2019年3月在Sirtex Medical Ltd担任全球首席财务官和公司秘书。Smith先生在执行财务方面拥有超过20年的经验，并在包括生命科学在内的广泛行业为上市、私营、国际和澳大利亚政府组织提供一般管理经验。Smith先生拥有澳大利亚新南威尔士大学工商管理硕士学位（MBA）和西悉尼大学商学学士学位（会计学）。资深注册会计师20年。
Darren Smith,has served as Telix Pharmaceuticals Limited Group Chief Financial Officer since August 2022. Previously, he was Global Chief Financial Officer and Company Secretary at Sirtex Medical Ltd from June 2008 to March 2019. Mr. Smith has over 20 years of experience in executive finance and general management experience across a broad range of industries, including life-sciences, for publicly listed, private, international, and Australian government organizations. Mr. Smith holds a Master of Business Administration (MBA) from the University of New South Wales in Australia and a Bachelor of Business (Accounting) from Western Sydney University. He has been a Fellow Certified Practicing Accountant for 20 years.- Darren Smith，自2022年8月起担任Telix Pharmaceuticals Limited Group 首席财务官。此前，他于2008年6月至2019年3月在Sirtex Medical Ltd担任全球首席财务官和公司秘书。Smith先生在执行财务方面拥有超过20年的经验，并在包括生命科学在内的广泛行业为上市、私营、国际和澳大利亚政府组织提供一般管理经验。Smith先生拥有澳大利亚新南威尔士大学工商管理硕士学位（MBA）和西悉尼大学商学学士学位（会计学）。资深注册会计师20年。
- Darren Smith,has served as Telix Pharmaceuticals Limited Group Chief Financial Officer since August 2022. Previously, he was Global Chief Financial Officer and Company Secretary at Sirtex Medical Ltd from June 2008 to March 2019. Mr. Smith has over 20 years of experience in executive finance and general management experience across a broad range of industries, including life-sciences, for publicly listed, private, international, and Australian government organizations. Mr. Smith holds a Master of Business Administration (MBA) from the University of New South Wales in Australia and a Bachelor of Business (Accounting) from Western Sydney University. He has been a Fellow Certified Practicing Accountant for 20 years.
- David Cade
David Cade，自2024年1月起担任Telix Pharmaceuticals Limited集团首席医疗官。在过渡担任这一职务之前，他于2021年5月至2023年12月担任Telix Pharmaceuticals Limited亚太区业务的首席执行官，并于2019年10月至2021年4月担任我们的首席业务官兼投资者关系主管。此前，他曾于2007年1月至2017年9月担任Sirtex Medical Limited的首席医疗官，并于2017年10月至2019年9月担任Cochlear Limited的首席医疗官。他获得了莫纳什医学院的医学学士和外科学士学位（MBB），以及墨尔本商学院和巴塞罗那ESADE商业与法学院的工商管理硕士学位（MBA）。他还是澳大利亚公司董事学会的毕业生。
David Cade,has served as Telix Pharmaceuticals Limited Group Chief Medical Officer since January 2024. Prior to transitioning to this role, he was the Chief Executive Officer of Telix Pharmaceuticals Limited Asia Pacific operations from May 2021 to December 2023 and Telix Pharmaceuticals Limited Chief Business Officer and Head of Investor Relations from October 2019 to April 2021. Previously, he served as Chief Medical Officer at Sirtex Medical Limited from January 2007 to September 2017 and Chief Medical Officer at Cochlear Limited from October 2017 to September 2019. He received a Bachelor of Medicine and Bachelor of Surgery (MBBS) from Monash Medical School and a Master of Business Administration (MBA) from Melbourne Business School and ESADE Business and Law School Barcelona. He is also a Graduate of the Australian Institute of Company Directors.- David Cade，自2024年1月起担任Telix Pharmaceuticals Limited集团首席医疗官。在过渡担任这一职务之前，他于2021年5月至2023年12月担任Telix Pharmaceuticals Limited亚太区业务的首席执行官，并于2019年10月至2021年4月担任我们的首席业务官兼投资者关系主管。此前，他曾于2007年1月至2017年9月担任Sirtex Medical Limited的首席医疗官，并于2017年10月至2019年9月担任Cochlear Limited的首席医疗官。他获得了莫纳什医学院的医学学士和外科学士学位（MBB），以及墨尔本商学院和巴塞罗那ESADE商业与法学院的工商管理硕士学位（MBA）。他还是澳大利亚公司董事学会的毕业生。
- David Cade,has served as Telix Pharmaceuticals Limited Group Chief Medical Officer since January 2024. Prior to transitioning to this role, he was the Chief Executive Officer of Telix Pharmaceuticals Limited Asia Pacific operations from May 2021 to December 2023 and Telix Pharmaceuticals Limited Chief Business Officer and Head of Investor Relations from October 2019 to April 2021. Previously, he served as Chief Medical Officer at Sirtex Medical Limited from January 2007 to September 2017 and Chief Medical Officer at Cochlear Limited from October 2017 to September 2019. He received a Bachelor of Medicine and Bachelor of Surgery (MBBS) from Monash Medical School and a Master of Business Administration (MBA) from Melbourne Business School and ESADE Business and Law School Barcelona. He is also a Graduate of the Australian Institute of Company Directors.